Table 1 Comparison in demographic and clinical characteristics between sarcopenic and non-sarcopenic subjects at IPF diagnosis

Demographics and clinical characteristics at IPF diagnosis

Male gender—N(%)

50 (78.13%)

17 (89.47%)

67 (80.72%)

0.3404

Age at enrollment—Mean (SD)

71.6 (6.9)

75.6 (6.1)

72.5 (6.9)

0.0162

BMI—Mean (SD)

28.0 (3.9)

26.6 (4.4)

27.6 (4.0)

0.1198

GAP stage*—N(%)

0.0223

 1

22 (34.38%)

1 (5.26%)

23 (27.71%)

 2

29 (45.31%)

15 (78.95%)

44 (53.01%)

 3

12 (18.75%)

3 (15.79%)

15 (18.07%)

FVC%—Mean (SD)

89.5 (22.1)

73.2 (12.6)

85.7 (21.3)

0.0015

DLCO%—Mean (SD)

56.5 (19.0)

46.8 (15.4)

54.2 (18.6)

0.0442

6MWT (meters walked)*—Mean (SD)

409.4 (114.0)

382.6 (102.0)

403.2 (111.3)

0.3387

Comorbidities—N(%)

 Arrhythmia

6 (9.38%)

2 (10.53%)

8 (9.64%)

1

 Congestive heart failure

2 (3.13%)

0 (0.00%)

2 (2.41%)

1

 Coronary artery disease

10 (15.63%)

4 (21.05%)

14 (16.87%)

0.7276

 Previous solid neoplasm

10 (15.63%)

3 (15.79%)

13 (15.66%)

1

 Dysthyroidism

0.7374

  Hyperthyroidism

2 (3.13%)

0 (0.00%)

2 (2.41%)

  Hypothyroidism

2 (3.13%)

1 (5.26%)

3 (3.61%)

 MRGE

17 (26.56%)

2 (10.53%)

19 (22.89%)

0.2158

 Osteoporosis

5 (7.81%)

1 (5.26%)

6 (7.23%)

1

 Sleep apnea

2 (3.13%)

2 (10.53%)

4 (4.82%)

0.2235

 Anxiety an depression

5 (7.81%)

1 (5.26%)

6 (7.23%)

1

 Chronic liver disease

5 (7.81%)

1 (5.26%)

6 (7.23%)

1

 Pulmonary hypertension

0 (0.00%)

1 (5.26%)

1 (1.21%)

0.2289

 Vasculopathy

8 (12.50%)

1 (5.26%)

9 (10.84%)

0.6768

 Diabetes

7 (10.94%)

3 (15.79%)

10 (12.05%)

0.6888

 Hypertension

26 (40.63%)

7 (36.84%)

33 (39.76%)

1

N comorbidities

0.7673

 0–2

38 (59.38%)

12 (63.16%)

50 (60.24%)

 ≥ 3

26 (40.63%)

7 (36.84%)

33 (39.76%)

Physical performance and nutritional risk screening

Physical activity, IPAQ

0.0028

 Mean MET (SD)

2.382 (3.296)

9.92 (1.734)

2.077 (3.069)

% weight loss in 6 months > 5%—N(%)

6 (9.38%)

3 (15.79%)

9 (10.84%)

0.421